FibroGen, Inc.
FibroGen, Inc., a leading biotechnology company headquartered in the United States, focuses on developing innovative therapies for serious diseases. Founded in 1993, FibroGen has made significant strides in the fields of anaemia, fibrosis, and other critical health conditions, establishing itself as a key player in the biopharmaceutical industry. The company is renowned for its core product, Roxadustat, a novel treatment for anaemia associated with chronic kidney disease, which has garnered attention for its unique mechanism of action. With a strong presence in both the US and international markets, FibroGen continues to expand its portfolio, aiming to address unmet medical needs and improve patient outcomes. The company’s commitment to research and development has positioned it as a notable innovator in the biotechnology landscape.
DitchCarbon Score
How does FibroGen, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
FibroGen, Inc.'s score of 18 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
FibroGen, Inc.'s reported carbon emissions
FibroGen, Inc., headquartered in the US, currently does not have publicly available carbon emissions data or specific reduction targets. As such, there are no reported figures for their Scope 1, 2, or 3 emissions. The absence of emissions data suggests that the company may still be in the early stages of formalising its climate commitments or reporting practices. In the context of the pharmaceutical industry, many companies are increasingly focusing on sustainability and climate action, often setting ambitious targets to reduce their carbon footprint. However, without specific initiatives or commitments disclosed by FibroGen, it is unclear what steps they are taking towards climate responsibility. As the industry evolves, it is anticipated that FibroGen will align with broader trends in sustainability, potentially adopting reduction targets and strategies in the future.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
FibroGen, Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
